Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 9390

Similar articles for PubMed (Select 18035185)

1.
2.

Recent changes in the landscape of combination RAS blockade.

Epstein BJ, Smith SM, Choksi R.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1373-84. doi: 10.1586/erc.09.127. Review.

PMID:
19900020
3.

RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, Böhm M.

Clin Res Cardiol. 2008 Jul;97(7):418-31. doi: 10.1007/s00392-008-0668-3. Epub 2008 May 3. Review.

PMID:
18454336
4.

Blocking the renin-angiotensin system: dual- versus mono-therapy.

Ravandi A, Teo KK.

Expert Rev Cardiovasc Ther. 2009 Jun;7(6):667-74. doi: 10.1586/erc.09.47. Review.

PMID:
19505282
5.

Angiotensin II type 1 receptor blockade: high hopes sent back to reality?

Grothusen A, Divchev D, Luchtefeld M, Schieffer B.

Minerva Cardioangiol. 2009 Dec;57(6):773-85. Review.

PMID:
19942847
6.

Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.

Cohn JN, Goldman JM.

Am J Hypertens. 2008 Mar;21(3):248-56. doi: 10.1038/ajh.2007.56. Epub 2008 Jan 24. Review.

PMID:
18219303
7.

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Werner C, Pöss J, Böhm M.

Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Review.

PMID:
20568830
8.

Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.

Doulton TW, MacGregor GA.

J Renin Angiotensin Aldosterone Syst. 2009 Dec;10(4):185-9. doi: 10.1177/1470320309342733. Epub 2009 Jul 17.

PMID:
19617273
9.
10.

ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.

Düsing R, Sellers F.

Curr Med Res Opin. 2009 Sep;25(9):2287-301. doi: 10.1185/03007990903152045. Review.

PMID:
19635044
11.

Angiotensin receptor blockers: evidence for preserving target organs.

Carson P, Giles T, Higginbotham M, Hollenberg N, Kannel W, Siragy HM.

Clin Cardiol. 2001 Mar;24(3):183-90.

PMID:
11288962
12.
13.
16.

Inhibition of the renin-angiotensin system and the prevention of stroke.

Schrader J, Kulschewski A, Dendorfer A.

Am J Cardiovasc Drugs. 2007;7(1):25-37.

PMID:
17355164
17.

Recommendations for the management of special populations: renal disease in diabetes.

Raij L.

Am J Hypertens. 2003 Nov;16(11 Pt 2):46S-49S. Review.

PMID:
14625161
18.

Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.

Nosadini R, Tonolo G.

J Am Soc Nephrol. 2002 Nov;13 Suppl 3:S216-23. Review.

19.

Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.

Bommer WJ.

Prev Cardiol. 2008 Fall;11(4):215-22. doi: 10.1111/j.1751-7141.2008.00004.x. Review.

PMID:
19476574
20.

ACE inhibitors in heart failure: what more do we need to know?

Demers C, Mody A, Teo KK, McKelvie RS.

Am J Cardiovasc Drugs. 2005;5(6):351-9. Review.

PMID:
16259523
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk